A virus NT was performed in a biosafety level 3 laboratory to determine the titers. A SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) was designed to detect neutralizing antibodies in the serum, based on the binding affinity of SARS-CoV-2 viral protein 1viral protein 2 to antibodies. ELISA results viral protein 12, generated comparable neutralizing antibody titers. The results analyzed by spline regressiontwo-variable generalized additive model precisely reflected the real NT value. Our method can serve as a surrogate to quantify neutralizing antibody titer.

Due to the recent outbreak of COVID-19ongoing mutants, we developed a coronavirus variant protein microarray that includes all the current spike mutationsthe wild-type viral antigensapplied in detecting immune responsesdrug specificities. We filed the patientspublished our findings in the Analytical Chemistry. Besides massive production of the coronavirus protein microarray, we also collaborated with a scanner company, developed artificial intelligence software,collaborated with suppliers. We are welcome any sort of collaboration.

The invention integrates a variety of technologies including stem cell proliferation, directed inductioncryopreservation in vitro. This integrated system was developed under chemical defined condition,can expand various type of stem cells over one hundred foldcan furtherly induce to specific mature cells up to ten millions. In addition, the amount of cryoprotectant can be significantly reduced to 2 in the cryopreservation system with excellent cell survival rate. This integrated system can provide a promisingvarious stem cell sources for cell therapyimmunotherapy.